The Aachen-based pharma Paion (Germany), has been forced to axe a European phase III trial for a Surgical sedative, after failing to recruit enough patients. The company will instead focus its efforts on its ongoing US trials.
This is a blow to Paion’s pipeline, which is led by Remimazolam. The company stock price decreased almost 40%, but it has picked up again in the last few days.
Remimazolam is an ultra-short-acting intravenous sedative and anaesthetic from the benzodiazepines class. These agents have the advantage of being counteracted (with a molecule called flumazenil) allowing its rapid termination of its effect if necessary.
It is also not metabolized by liver tissues, so it should be safe for patients with liver disease or complications.
The trial in question intended to study the efficacy and safety of Remimazolam as a sedative in general anaesthesia, prior to cardiac surgery. It started in August 2015, with the objective of recruiting 530 patients in Leipzig (Germany).